In preclinical studies, seralutinib inhibited the PDGF-BB-induced proliferation of H1703 cells (a PDGFRα-driven lung cancer cell line), human PASMCs (which express similar levels of PDGFRα and PDGFRβ), and human lung fibroblasts (HLF, which express higher levels of PDGFRβ than PDGFRα) with half maximal inhibitory concentrations (IC50) of 32 nM, 33 nM, and 29 nM, respectively (Table 1) [7]. Here, PDGFRB is linked to lung carcinoma.